Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Biologic response modifiers in chronic hepatitis C

V Carreño1, J A Quiroga

  • 1Hepatology Unit, Fundación Jiménez Díaz, Madrid, Spain.

Journal of Hepatology
|January 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Review article: management of chronic hepatitis C in patients with contraindications to anti-viral therapy.

Alimentary pharmacology & therapeutics·2013
Same author

Phase-shifting interferometry corrupted by white and non-white additive noise.

Optics express·2011
Same author

Design of phase-shifting algorithms by fine-tuning spectral shaping.

Optics express·2011
Same author

Stable-marriages algorithm for preprocessing phase maps with discontinuity sources.

Applied optics·2010
Same author

Phase-unwrapping algorithm based on an adaptive criterion.

Applied optics·2010
Same author

Phase-unwrapping algorithm for noisy phase-map processing.

Applied optics·2010
Same journal

Anserine restores antibacterial immunity in cirrhosis via a protective CCL5-mediated hepatocyte-CD44<sup>+</sup>pDC crosstalk.

Journal of hepatology·2026
Same journal

Anti-CCL2-conjugated platelets attenuate early allograft and ischemia-reperfusion injury by inhibiting monocyte infiltration.

Journal of hepatology·2026
Same journal

A precision randomized trial of hepatitis C treatment support among people who inject drugs in India: The STOP-C Trial.

Journal of hepatology·2026
Same journal

Response to "Single-nucleus and spatial transcriptomic analyses reveal intra-tissue heterogeneity of PNPLA3".

Journal of hepatology·2026
Same journal

One-stop liquid biopsy: Can a single blood sample reveal the full spectrum of liver disease?

Journal of hepatology·2026
Same journal

Nocturnal insulin resistance and reduced insulin availability in human MASLD.

Journal of hepatology·2026
See all related articles

Biologic response modifiers like colony-stimulating factors and interleukins show promise in treating chronic viral hepatitis. Their use, alone or with interferon-alpha, is reviewed for chronic hepatitis C therapy.

Area of Science:

  • Immunology
  • Hepatology
  • Pharmacology

Background:

  • Biologic response modifiers encompass colony-stimulating factors and interleukins.
  • These agents are valuable in treating diverse diseases and preventing hematologic disorders.

Purpose of the Study:

  • To review the biologic effects of these modifiers.
  • To examine the rationale for their use in chronic viral hepatitis.
  • To assess their efficacy alone or combined with interferon-alpha for chronic hepatitis C.

Main Methods:

  • Literature review of biologic response modifiers.
  • Analysis of their application in viral hepatitis treatment.
  • Evaluation of combination therapy with interferon-alpha.

Related Experiment Videos

Main Results:

  • Colony-stimulating factors and interleukins demonstrate therapeutic benefits.
  • These modifiers can prevent hematologic disorders.
  • Their role in chronic hepatitis C treatment is under investigation.

Conclusions:

  • Biologic response modifiers offer potential therapeutic strategies for chronic viral hepatitis.
  • Further research is warranted to optimize their use in chronic hepatitis C.
  • Combination therapy with interferon-alpha may enhance treatment outcomes.